中西医结合治疗190例老年胰腺癌的预后分析

潘岩; 刘鲁明; 陈震; 孟志强; 林钧华; 陈颢; 沈晔华

doi:10.3969/j.issn.1001-5256.2014.04.011

中西医结合治疗190例老年胰腺癌的预后分析

DOI: 10.3969/j.issn.1001-5256.2014.04.011

复旦大学附属肿瘤医院中西医结合科

基金项目:

国家自然科学基金资助项目(81173461,81072942)；

详细信息

中图分类号: R735.9
计量
- 文章访问数: 3661
- HTML全文浏览量: 18
- PDF下载量: 748
- 被引次数: 0
出版历程
- 收稿日期: 2013-08-12
- 出版日期: 2014-04-20

Prognostic analysis of 190 elderly patients with pancreatic cancer treated by integrated traditional Chinese and Western medicine therapy

Department of Integrative Oncology, Fudan University Shanghai Cancer Center

Research funding:

摘要

摘要:
目的通过临床回顾性研究对以清胰化积方为主的中西医综合治疗老年胰腺癌进行疗效评估,探讨可行性治疗模式。方法采用Kaplan-Meier方法计算生存期,Log-rank检验进行组间比较,并通过应用Cox比例风险模型对2002年1月至2008年12月期间接受中西医结合治疗的190例老年胰腺癌患者进行多因素分析。结果本组190例老年胰腺癌患者:1年生存率28.42%;3年生存率6.32%;5年生存率2.11%。中位生存期为7.1个月。其中清胰化积组102例,中位生存期8.7个月;非清胰化积方88例,中位生存期4.7个月,差异有统计学意义（P<0.05）。KPS评分<80、CA19-9≥500 U/ml、消瘦（体重在6个月内减轻≥10%）、肝转移、手术方式、全身化疗和清胰化积中药是影响该治疗模式预后的独立影响因子。结论根治手术、全身化疗和清胰化积中药是老年胰腺癌长期生存保护因素。老年胰腺癌Ⅲ期患者可化疗结合清胰化积方中药治疗,Ⅳ期老年胰腺癌患者则应以中药及最佳对症支持治疗为主。
- 胰腺肿瘤 /
- 中西医结合疗法 /
- 老年人 /
- 预后
Abstract:
Objective To evaluate the clinical effect of integrated traditional Chinese and Western medicine therapy based on Qingyi Huaji (QYHJ) formula (for clearing the pancreas and dissolving the stasis) in the elderly patients with pancreatic cancer by a retrospective study and to explore a feasible treatment modality for this disease.Methods The data of 190 elderly pancreatic cancer patients (≥ 60 years) , who received integrated traditional Chinese and Western medicine therapy from January 2002 to December 2008, were retrospectively reviewed.These patients were assigned to receive QYHJ formula or non- QYHJ formula.The Kaplan- Meier method was used for calculating survival rates, and the log- rank test was used for survival difference analysis;multivariate analysis was performed using the Cox proportional hazards model.Results The 1-, 3-, and 5- year survival rates of the 190 patients were 28.42%, 6.32%, and 2.11%, respectively, and the median survival was 6.7 months.The QYHJ group (n = 102) had a significantly longer median survival than the non- QYHJ group (n = 88) (8.7 months vs 4.7 months, P < 0.05) .For the elderly patients with pancreatic cancer, KPS < 80, CA19- 9≥500 U / ml, weight loss (≥10% within six months) , and liver metastasis were poor prognostic factors, while radical surgery, systemic chemotherapy, and QYHJ formula were favorable prognostic factors.Conclusion Radical surgery, systemic chemotherapy, and QYHJ formula are protective factors for long- term survival in elderly patients with pancreatic cancer.Combination therapy with chemotherapy and QYHJ formula is suitable for elderly patients with stage Ⅲ pancreatic cancer, while herbal formula combined with the optimal symptomatic and supportive treatment are suitable for those with stage Ⅳ pancreatic cancer.
- pancreatic neoplasms /
- TCM WM therapy /
- aged /
- prognosis

HTML全文

参考文献(12)

[1]SIEGEL R, NAISHADHAM D, JEMAL A.Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63 (1) :11-30.

[2]GU K, WU CX, BAO PP, et al.Incidence of pancreatic cancer in Shanghai:a current, retrospective and comparative exploration[J].J Surg Concepts Pract, 2009, 14 (5) :510-515. (in Chinese) 顾凯, 吴春晓, 鲍萍萍, 等.上海市胰腺癌流行现况、回顾与比较分析[J].外科理论与实践, 2009, 14 (5) :510-515.

[3]LIU LM, WU LC, LIN SY, et al.Therapeutic evaluation on advanced pancreatic cancer treated by integrative Chinese and Western medicine-clinical analysis of 56 cases[J].Chin J Integr Med, 2003, 9 (1) :39-43.

[4]OUYANG HQ, WANG P, MENG ZQ, et al.Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine[J].Pancreas, 2011, 40 (1) :120-125.

[5]SHEN YH, LIU LM, CHEN Z, et al.Study on Chinese medicine combined with chemotherapy for treatment of 32 cases of advanced pancreatic cancer[J].J Tradit Chin Med, 2006, 47 (2) :115-117. (in Chinese) 沈晔华, 刘鲁明, 陈震, 等.中药联合化疗治疗晚期胰腺癌32例临床研究[J].中医杂志, 2006, 47 (2) :115-117.

[6]SHORE S, VIMALACHANDRAN D, RARATY MG, et al.Cancer in the elderly:pancreatic cancer[J].Surg Oncol, 2004, 13 (4) :201-210.

[7]OUAISSI M, SIELEZNEFF I, PIRRO N, et al.Pancreatic cancer and pancreaticoduo-denectiomy in elderly patient:morbidity and mortality are increased.Is it the real life?[J].Hepatogastroenterology, 2008, 55 (88) :2242-2246.

[8]STORNIOLO AM, ENAS NH, BROWN CA, et al.An investigational new drug treatment program for patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma[J].Cancer, 1999, 85 (6) :1261-1268.

[9]GLEISNER AL, ASSUMPCAO L, CAMERON JL, et al.Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?[J].Cancer, 2007, 110 (11) :2484-2492.

[10]HWANG SI, KIM HO, SON BH, et al.Surgical palliation of unresectable pancreatic head cancer in elderly patients[J].World J Gastroenterol, 2009, 15 (8) :978-982.

[11]MARECHAL R, DEMOLS A, GAY F, et al.Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer[J].Pancreas, 2008, 36 (3) :16-21.

[12]WEBER A, KEHL V, MITTERMEYER T, et al.Prognostic factors for survival in patients with unresectable pancreatic cancer[J].Pancreas, 2010, 39 (8) :1247-1253.

施引文献

资源附件(0)

访问统计